Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / CDMOP - Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30 2024 After Market Close on July 2 2024


CDMOP - Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30 2024 After Market Close on July 2 2024

TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and fiscal year ended April 30, 2024, and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events .

About Avid Bioservices, Inc.

Avid Bioservices (NASDAQ:CDMO) is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With more than 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com


Contacts:Stephanie Diaz (Investors)Vida Strategic Partners415-675-7401sdiaz@vidasp.comTim Brons (Media)Vida Strategic Partners415-675-7402tbrons@vidasp.com

Stock Information

Company Name: Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock
Stock Symbol: CDMOP
Market: NASDAQ
Website: avidbio.com

Menu

CDMOP CDMOP Quote CDMOP Short CDMOP News CDMOP Articles CDMOP Message Board
Get CDMOP Alerts

News, Short Squeeze, Breakout and More Instantly...